EVI1 As a Marker for Lymph Node Metastasis in HNSCC

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Feb 5

PMID 32013033

Citations 15

Authors

Christian Idel

Julika Ribbat-Idel

Patrick Kuppler

Rosemarie Krupar

Anne Offermann

Wenzel Vogel

Dirk Rades

Jutta Kirfel

Barbara Wollenberg

Sven Perner

Affiliations

Soon will be listed here.

Abstract

Background: HNSCC is the sixth most common cancer in humans and has still a very poor prognosis. The treatment methods so far are very often associated with mutilation and impairment in the quality of life. Except for p16 expression, there are no reliable prognostic markers in HNSCC so far. Ecotropic Viral Integration Site 1 (EVI1) is a well-described prognostic marker in leukemia and different types of solid cancers. In these, a high EVI1 expression is associated with a poor prognosis. In HNSCC, it is not known so far if EVI1 has any prognostic relevance.

Materials And Methods: We used our representative tissue cohort of 389 primary HNSCCs, of which 57.2% had one or more lymph node metastases. Here EVI1 expression was analyzed via immunohistochemistry and correlated with the clinical characteristics of these patients.

Results: Although in HNSCC EVI1 expression does not predict poor survival, a high EVI1 expression in the primary tumor correlates with a lymph node metastatic disease.

Conclusion: Consequently, EVI1 may serve as a biomarker to predict an occult lymph node metastasis in a clinical nodal negative (cN0) HNSCC.

Citing Articles

PKM2 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating epithelial-mesenchymal transition: an experimental research.

Zhou X, Li Y, Pan M, Lu T, Liu C, Wang Z Diagn Pathol. 2024; 19(1):48.

PMID: 38431604 PMC: 10907999. DOI: 10.1186/s13000-024-01474-5.

Phosphoglycerate-kinase-1 Is a Potential Prognostic Biomarker in HNSCC and Correlates With Immune Cell Infiltration.

Wang P, Wang Y, Xu Y, Zhang C, Wang K, Wang Q Cancer Genomics Proteomics. 2023; 20(6suppl):723-734.

PMID: 38035710 PMC: 10687726. DOI: 10.21873/cgp.20419.

SOCS1 as a Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas.

Guo M, Zhang L, Wang H, Zhou Q, Zhu X, Fu X Curr Issues Mol Biol. 2023; 45(7):5598-5612.

PMID: 37504269 PMC: 10378037. DOI: 10.3390/cimb45070353.

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC.

VON Bernuth A, Ribbat-Idel J, Klapper L, Jagomast T, Rades D, Leichtle A Int J Mol Sci. 2023; 24(6).

PMID: 36982215 PMC: 10048917. DOI: 10.3390/ijms24065140.

Identifying KRT20 as a Potential Key Gene in Lymphatic Metastasis of Head and Neck Squamous Cell Carcinoma.

Zhang Y, Huang Q, Huang H, Ren H, Zhou L Technol Cancer Res Treat. 2022; 21:15330338221107710.

PMID: 35815926 PMC: 9340431. DOI: 10.1177/15330338221107710.

References

Parker S, Tong T, Bolden S, Wingo P . Cancer statistics, 1996. CA Cancer J Clin. 1996; 46(1):5-27. DOI: 10.3322/canjclin.46.1.5. View

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

Forster M, Devlin M . Immune Checkpoint Inhibition in Head and Neck Cancer. Front Oncol. 2018; 8:310. PMC: 6123367. DOI: 10.3389/fonc.2018.00310. View

Braun M, Kirsten R, Rupp N, Moch H, Fend F, Wernert N . Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 2013; 28(5):605-10. DOI: 10.14670/HH-28.605. View

Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y . Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2010; 117(23):6304-14. DOI: 10.1182/blood-2009-07-234310. View

Stell P, Rawson N . Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990; 61(5):779-87. PMC: 1971597. DOI: 10.1038/bjc.1990.175. View

Sattler H, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H . Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 2000; 45(3):207-15. DOI: 10.1002/1097-0045(20001101)45:3<207::aid-pros2>3.0.co;2-h. View

Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P . EVI1 promotes tumor growth via transcriptional repression of MS4A3. J Hematol Oncol. 2015; 8:28. PMC: 4389965. DOI: 10.1186/s13045-015-0124-6. View

De Braekeleer M, Le Bris M, De Braekeleer E, Basinko A, Morel F, Douet-Guilbert N . 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015; 11(11):1675-86. DOI: 10.2217/fon.15.64. View

10.

Chin D, Boyle G, Porceddu S, Theile D, Parsons P, Coman W . Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006; 6(7):1111-8. DOI: 10.1586/14737140.6.7.1111. View

11.

Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y . Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene. 2014; 33(42):5028-38. PMC: 4217142. DOI: 10.1038/onc.2014.108. View

12.

Hufbauer M, Maltseva M, Meinrath J, Lechner A, Beutner D, Huebbers C . HPV16 increases the number of migratory cancer stem cells and modulates their miRNA expression profile in oropharyngeal cancer. Int J Cancer. 2018; 143(6):1426-1439. DOI: 10.1002/ijc.31538. View

13.

Lydiatt W, Patel S, OSullivan B, Brandwein M, Ridge J, Migliacci J . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-137. DOI: 10.3322/caac.21389. View

14.

LARSON D, Lindberg R, Lane E, Goepfert H . Major complications of radiotherapy in cancer of the oral cavity and oropharynx. A 10 year retrospective study. Am J Surg. 1983; 146(4):531-6. DOI: 10.1016/0002-9610(83)90247-7. View

15.

Urashima M, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C . Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. PLoS One. 2013; 8(11):e80828. PMC: 3835411. DOI: 10.1371/journal.pone.0080828. View

16.

Dutta P, Bui T, Bauckman K, Keyomarsi K, Mills G, Nanjundan M . EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol. 2013; 7(3):647-68. PMC: 3805042. DOI: 10.1016/j.molonc.2013.02.008. View

17.

Konantz M, Andre M, Ebinger M, Grauer M, Wang H, Grzywna S . EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia. 2012; 27(1):56-65. DOI: 10.1038/leu.2012.211. View

18.

. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017; 543(7645):378-384. PMC: 5354998. DOI: 10.1038/nature21386. View

19.

Ervin T, Clark J, Weichselbaum R, Fallon B, Miller D, Fabian R . An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987; 5(1):10-20. DOI: 10.1200/JCO.1987.5.1.10. View

20.

Nayak K, Sajitha I, Santhosh Kumar T, Chakraborty S . Ecotropic viral integration site 1 promotes metastasis independent of epithelial mesenchymal transition in colon cancer cells. Cell Death Dis. 2018; 9(2):18. PMC: 5833819. DOI: 10.1038/s41419-017-0036-1. View